AN2 Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $69,635,000.
Profit Margin
| 2019 | 0 | -5.63M | |
|---|---|---|---|
| 2020 | 0 | -13.6M | |
| 2021 | 0 | -21.47M | |
| 2022 | 0 | -41.47M | |
| 2023 | 0 | -64.73M |
ANTX Income Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Revenue | |||||
Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 0 | 77K | 0 | 0 | 0 |
Gross profit | 0 | -77K | 0 | 0 | 0 |
Operating exp. | |||||
Research and development | 54.87M | 29.51M | 16.90M | 6.01M | 4.88M |
Selling and marketing | 0 | 0 | 0 | 0 | 287.26K |
Total operating expenses | 69.63M | 42.26M | 21.57M | 7.28M | 5.17M |
Operating income | -69.63M | -42.26M | -21.57M | -7.28M | -5.17M |
Other income (expenses), net | 4.90M | 1.30M | 31K | -6.31M | -457K |
Income before tax | -64.73M | -40.95M | -21.54M | -13.60M | -5.63M |
Income tax expense | 0 | 514K | -69K | -3K | -31.06K |
Net income | -64.73M | -41.47M | -21.47M | -13.6M | -5.63M |
Earnings per share | |||||
Basic EPS | -2.74 | -2.14 | -1.15 | -0.73 | -0.3 |
Diluted EPS | -2.74 | -2.14 | -1.15 | -0.73 | -0.3 |
| Data source | Data source |